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Predictive accuracya b s t r a c t
Objective: To assess the accuracy of ﬁrst trimester soluble fms-like tyrosine kinase-1 (sFlt-1)
and placental growth factor (PlGF) in predicting pregnancy hypertension and pre-eclampsia;
and compare with the accuracy of routinely collected maternal and clinical risk factors.
Study design: In this population-based cohort study, serum sFlt-1 and PlGF levels weremea-
sured in ﬁrst trimester in 2,681womenwith singletonpregnancies inNewSouthWales, Aus-
tralia.
Main outcome measures: Prediction of pregnancy hypertension and pre-eclampsia.
Results: There were 213 (7.9%) women with pregnancy hypertension, including 68 (2.5%)
with pre-eclampsia. The area under the curve (AUC) for both sFlt-1 and PlGF was not differ-
ent from chance, but combined was 0.55 (P = 0.005). Parity and previous diagnosed hyper-
tension had better predictive accuracy than serum biomarkers (AUC = 0.64, P < 0.001) and
the predictive accuracy for all maternal and clinical information was fair (AUC = 0.70,
P < 0.001 for pregnancy hypertension and AUC = 0.74, P < 0.001 for pre-eclampsia). Adding
sFlt-1 and PlGF to maternal risk factors did not improve the ability of the models to predict
pregnancy hypertension or pre-eclampsia.
Conclusions: Maternal ﬁrst trimester serum concentrations of sFlt-1 and PlGF do not predict
hypertensive disorders in pregnancy any better than routinely collected clinical and mater-
nal risk factor information. Screening for sFlt-1 and PlGF levels in early pregnancywould not
identify those pregnancies at-risk.
 2013 The Authors. Published by Elsevier B.V. on behalf of International Society for the
Study of Hypertension in Pregnancy. Open access under CC BY-NC-ND license.IntroductionHypertensive disorders of pregnancy have a major im-
pact on maternal health and are responsible for 9–25% of
deaths worldwide [1] and encompass two different
conditions. Chronic hypertension has onset prior to preg-
nancy or is diagnosed prior to 20 week gestation. Pregnancy
hypertension has onset from 20 week gestation and ranges
from hypertension alone (gestational hypertension)
through proteinuria and multi-organ dysfunction (pre-
eclampsia) to seizures (eclampsia). While these broad
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for each subgroup vary internationally. Pregnancy hyper-
tension and pre-eclampsia are of particular interest because
if women at risk can be identiﬁed early in pregnancy this
would allow ample time for monitoring and implementing
preventive strategies.
The pathogenesis of pre-eclampsia involves inadequate
remodelling of spiral arteries during placental development
[2], inﬂuenced by imbalances in expression of pro-
angiogenic factors such as placental growth factor (PlGF)
and anti-angiogenic fms-like tyrosine kinase-1 (sFlt-1)
receptor [3]. Serum concentrations of sFlt-1, PlGF and other
biomarkers of placental development have been suggested
to have predictive value along with several maternal and
clinical risk factors that can also help identifywomenat-risk
[4,5]. However, results have comemostly fromsmall studies
[6], and have been inconsistent and not reliable enough for
implementation in routine clinical practice. Evaluation of
biomarkers for their clinical utility needs to assess the
added beneﬁt they offer to risks that can be ascertained
from an antenatal booking history. The aim of this study
was to assess the accuracy of ﬁrst trimester fms-like tyro-
sine kinase-1 (sFlt-1) and placental growth factor (PlGF),
both alone and in combination, in predicting pregnancy
hypertension and pre-eclampsia in a population-based
cohort; and compare them with the accuracy of routinely
collected maternal and clinical risk factors.
Materials and methods
Study population and sample testing
The study population included pregnant women
attending ﬁrst trimester Down syndrome screening be-
tween July and October 2006 in New South Wales (NSW),
Australia. Serum samples were collected by the Paciﬁc Lab-
oratory Medicine Services (PaLMs), and then archived and
stored at 80 C. During this period this was the state’s
only public screening service and received samples from
throughout NSW.
Serum samples for this study were thawed and serum
levels of sFlt-1 were measured using a commercially avail-
able Quantakine ELISA kit (R&D Systems, USA) while PlGF
was measured by an automated immunoassay using com-
mercially available kits (AutoDELFIA PerkinElmer Inc. Tur-
ku, Finland). Intra-assay and inter-assay coefﬁcients of
variation were <12% and the reported analytic sensitivity
of the assay was 7.7–1980 pg/ml for sFlt-1 and 0.7–
168 pg/ml for PlGF. Laboratory scientists were blinded to
pregnancy outcomes.
Data sources
The laboratory database contained maternal informa-
tion for those with archived serum samples and women’s
corresponding pregnancy and birth outcomes were ascer-
tained from the Perinatal Data Collection (PDC) and the
Admitted Patient Data Collection (APDC), all three
sources were then combined via record linkage. The
PDC is a statutory surveillance system of all births in
NSW of at least 400 g birth weight, or at least 20 weekgestation and includes demographic, medical and obstet-
ric information on the mother, labour, delivery and birth
outcomes. The APDC is a census of all patient hospital
admissions from NSW public and private hospitals, with
records for both mothers and liveborn infants. It holds
demographic, clinical and health service information for
each admission. Relevant diagnoses and procedures are
also recorded for each hospital admission and coded
according to the International Classiﬁcation of Diseases
version 10-Australian Modiﬁcation (ICD10-AM) and
Australian Classiﬁcation of Healthcare Interventions,
respectively.
In Australia unit record data from multiple datasets
cannot be produced because unique identiﬁers are not
available for record linkage. Therefore, probabilistic link-
age methods are used [7,8]. This involves a complex pro-
cess of blocking and matching combinations of selected
variables (such as name, date of birth, address and hos-
pital) using record-linkage software [9]. The validity of
the probabilistic record linkage is extremely high with
less than 1% of records having an incorrect match [7–
9]. Record linkage was conducted by The NSW Centre
for Health Record Linkage (CHeReL) and identifying
information are removed before the data are sent to
researchers. The CHeReL assesses the linkage quality for
each study, and for this study there were <5/1000
missed links and <2/1000 false positive links. The study
was approved by the NSW Population and Health Ser-
vices Research Ethics Committee.
Study outcomes included were pregnancy hyperten-
sion and pre-eclampsia and to maximize ascertainment,
information was identiﬁed from both the APDC and
PDC data [10,11]. Pre-eclampsia (regardless of severity)
and any pregnancy hypertension (pre-eclampsia or gesta-
tional hypertension) were determined either if ‘Yes’ was
recorded in response to the relevant questions (proteinu-
ric or non proteinuric hypertension with onset >20 week)
in the PDC record, or if any APDC record had a diagnosis
of gestational hypertension (ICD10-AM: O13 and O16),
pre-eclampsia (O11 and O14) or eclampsia (O15) [11].
The key maternal and clinical risk factors used in this
analysis included maternal age and weight (kilograms)
ascertained at the time of ﬁrst trimester screening, parity
(nulliparous/multiparous), smoking during pregnancy,
any previously diagnosed hypertension (chronic or preg-
nancy) or high blood pressure, any previously diagnosed
diabetes (pre gestational or gestational), country of birth
and socio-economic disadvantage quintile. Socio-eco-
nomic disadvantage was determined using the Socio-Eco-
nomic Indexes for Areas (SEIFA) relative disadvantage
scores developed by the Australian Bureau of Statistics
(ABS) [12]. Information on Pregnancy Associated Plasma
Protein A (PAPP-A) from laboratory data (used for Down
syndrome screening) was also available for analysis. Only
factors that are well and accurately reported were in-
cluded in the analyses [13]. Maternal weight was missing
in 570 (21%) of the records. Multiple imputation was
used to account for the missing maternal weight, a tech-
nique that predicts missing values using existing values
from other variables [14] Other missing data were infre-
quent: there were no records with missing maternal age,
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Smoking was missing in 29 records (1.1%) and there
were 5 missing records for PAPP-A (0.2%) which were ex-
cluded from the analysis.
Statistical analysis
Comparison of maternal characteristics and concentra-
tions of sFlt-1 and PlGF between women with and without
each clinical outcome was performed using contingency
tables, student’s t-test or Wilcoxon-rank sum test for cate-
gorical, normal or non-normally distributed data, respec-
tively. As sFlt-1 and PlGF varied by gestational age,
weight and smoking status, levels were standardized using
multiple of the median (MoM) as described by Cuckle and
Wald [15]. Logarithmic transformation of sFlt-1 and PlGF
MoM was used to produce Gaussian distributions.
Univariate logistic regression analysis was performed to
assess associations between serum biomarkers and ad-
verse pregnancy outcomes. Multivariate logistic regression
analysis was then conducted to evaluate serum biomarkers
taking into account maternal factors identiﬁed in the liter-
ature to be associated with the outcomes of interest (par-
ity, weight, previous diagnosis of any hypertension).
Separate models were conducted, ﬁrstly evaluating just
serum biomarkers alone, and then serum biomarkers com-
bined, then maternal and clinical factors only (excluding
biomarkers) and ﬁnally a combined model including both
serum biomarkers and maternal risk factors. Each of these
models were compared to determine whether serum bio-
marker levels provided any additional information to
maternal and clinical risk factors in predicting pregnancy
hypertension and pre-eclampsia, by evaluating the differ-
ences in maximum likelihood estimates from each model
using the likelihood ratio test (X2).
The diagnostic performance of the models was deter-
mined by examining the area under the Receiver Operating
Characteristic (ROC) curves (AUC). A standardized scale
was then used to assess the AUC results [16], where an
AUC of 1 represents a perfect test, 0.9–<1 an excellent test,Table 1
Demographic characteristics and serum levels of PlGF, sFlt-1 and PAPP-A of the st
Variable Unaffected women n = 2468
Age (SD) 32.8 (4.7)
Maternal weight (SD) 66.3 (13.7)
Smoking (%) 150 (6.2)
Nulliparous (%) 1064 (43.9)
Country of birth (%)
Australia and New Zealand 1641 (66.5)
Asian countries 322 (13.1)
Other countries 505 (20.5)
Previously diagnosed hypertension (%) 139 (15.6)
Previously diagnosed diabetes (%) 61 (2.5)
PlGF pg/ml (IQR) 24.1 (18.3, 31.7)
sFlt-1 pg/ml (IQR) 286.8 (167.1, 472.1)
PAPP-A pg/ml (IQR) 1.71 (1.06, 2.79)
PlGF MoM (IQR) 1.01 (0.77, 1.31)
sFlt-1 MoM (IQR) 1.01 (0.60, 1.67)
PAPP-A MoM (IQR) 0.98 (0.66, 1.46)
SD: standard deviation; MoM: multiple of the median; IQR: interquartile range.
a P < 0.05.
b P < 0.001.0.8–<0.9 a good test, 0.7–<0.8 a fair test, 0.6–<0.7 a poor
test and 0.5–<0.6 a worthless test. AUC results were also
examined to determine whether models performed better
than chance (0.5). Finally, estimates of predictive accuracy
at a ﬁxed 5% false positive rate were calculated including
sensitivity, speciﬁcity, positive (PPV), negative predictive
values (NPV) and positive likelihood ratio with exact
binominal conﬁdence intervals. Models and predictive
accuracy were examined among all women and for a
sub-group of nulliparous women that have increased risk
of pregnancy hypertension or pre-eclampsia [2,5]. A P-va-
lue of <0.05 was considered to be statistically signiﬁcant
and analyses performed using SAS software 9.2 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
A total of 2973 serum samples were tested for sFlt-1
and PlGF; with health information relevant to the preg-
nancy available for 2,782 (93.6%) samples. We excluded
101 women whose blood sample was taken before 10 or
after 14 week gestation, had a medical abortion, had a twin
pregnancy or had an infant with a major congenital anom-
aly. A total of 2,681 women were included in the analysis.
Levels of sFlt-1 and PlGF were outside the limits of assay
detection for 40 and 6 women, respectively. Table 1 pre-
sents the maternal characteristics and biomarker levels
by pregnancy outcome. The mean (SD) maternal age was
32.8 (4.6) years, mean maternal weight was 66.9 (12.7)
kg, 1,182 (44.8%) women were nulliparous and 162
(6.1%) smoked during pregnancy. Compared to unaffected
pregnancies, women with pregnancy hypertension or
pre-eclampsia were heavier, were more likely to be having
their ﬁrst baby and to have been previously diagnosed
with hypertension.
Median [inter quartile range (IQR)] serum levels of sFlt-
1 and PlGF for the total cohort were 286.4 (167.1–466.8 pg/
ml) and 23.9 (18.1–31.5 pg/ml), respectively. There were
213 (7.9%) women diagnosed with pregnancy hyperten-
sion, including 68 (2.5%) with pre-eclampsia. Comparedudy population by pregnancy outcome.
Pregnancy hypertension n = 213 Pre-eclampsia n = 68
32.6 (4.3) 32.1 (4.1)
74.4 (18.0)b 72.8 (16.8)b
12 (5.6) 1 (1.5)
118 (55.7)b 44 (65.7)b
180 (84.5)b 50 (73.5)
11 (5.2)b 6 (8.8)
22 (10.3)b 12 (17.7)
40 (18.8)b 11 (16.2)b
11 (5.2)a 4 (5.9)
21.3 (16.9, 28.0)b 20.7 (17.2, 32.6)
272 (169.6, 441.7) 268.1 (164.8, 390.5)
1.41 (0.80, 2.14)b 1.34 (0.76, 2.4)a
0.92 (0.71, 1.24)b 0.92 (0.73, 1.31)
1.01 (0.62, 1.56) 0.82 (0.53, 1.46)
0.94 (0.62, 1.37) 0.83 (0.57, 1.32)
Fig. 1. Comparison of log sFlt-1 MoM and log PlGF MoM distributions in affected and unaffected pregnancies for pregnancy hypertension and pre-
eclampsia.
Table 2
Accuracy of models using serum biomarker levels and maternal and clinical information in early pregnancy to predict pregnancy hypertension and pre-
eclampsia based on a 5% false positive rate in all women.









Pregnancy hypertension (n = 213)
PlGF MoM 0.56 (0.52, 0.60) 0.005 6.1 (3.3, 10.3) 9.6 (5.2, 15.8) 92.2 (91.0, 93.2) 1.23
sFlt-1 MoM 0.52 (0.48, 0.55) 0.4 5.8 (3.0, 9.9) 9.0 (4.7, 15.2) 92.2 (91.1, 93.2) 1.17
PAPP-A MoM 0.53 (0.49, 0.57) 0.15 7.5 (4.4, 11.9) 11.8 (6.9, 18.4) 92.2 (91.1, 93.3) 1.54
Serum Biomarkers only 0.55 (0.51, 0.58) 0.005 6.3 (3.4, 10.5) 9.7 (5.3, 16.0) 92.3 (91.2, 93.3) 1.26
Previously diagnosed
hypertension + Parity
0.64 (0.60, 0.67) <0.0001 18.0 (13.0, 23.9) 21.5 (15.6, 28.4) 93.0 (91.9, 94.0) 3.17
All maternal and clinical
informationa
0.70 (0.67, 0.74) <0.0001 26.2 (20.3, 32.8) 31.2 (24.4, 38.7) 93.7 (92.7, 94.6) 5.25
Combined – biomarkers + maternal
and clinical information
0.70 (0.67, 0.74) <0.0001 24.8 (19.0, 31.2) 30.0 (23.2, 37.5) 93.6 (92.5, 94.5) 4.96
Pre-eclampsia (n = 68)
PlGF MoM 0.52 (0.45, 0.60) 0.5 7.4 (2.4, 17.3) 3.7 (1.2, 8.4) 97.5 (96.8, 98.1) 1.47
sFlt-1 MoM 0.56 (0.49, 0.62) 0.1 5.9 (1.6, 14.4) 3.0 (0.8, 7.6) 97.5 (96.8, 98.0) 1.18
PAPP-A MoM 0.57 (0.49, 0.64) 0.07 8.8 (3.3, 18.2) 4.4 (1.6, 9.4) 97.6 (96.9, 98.1) 1.77
Serum Biomarkers only 0.57 (0.50, 0.65) 0.04 7.4 (2.4, 16.3) 3.8 (1.2, 8.6) 97.5 (96.8, 98.1) 1.77
Previously diagnosed
hypertension + Parity
0.66 (0.60, 0.72) <0.0001 16.2 (8.4, 27.1) 6.4 (3.2, 11.2) 97.6 (97.0, 98.2) 2.53
All maternal and clinical informationa 0.74 (0.68, 0.80) <0.0001 25.0 (15.3, 37.0) 12.0 (7.1, 18.5) 97.9 (97.3, 98.4) 5.03
Combined – biomarkers + maternal
and clinical information
0.76 (0.70, 0.82) <0.0001 25.0 (15.3, 37.0) 12.0 (7.1, 18.5) 97.9 (97.3, 98.4) 5.03
a Including: maternal weight, smoking during pregnancy, parity, previously diagnosed hypertension, previously diagnosed diabetes, high blood pressure
recorded during pregnancy and country of birth; PPV: positive likelihood ratio; NPV: negative predictive value; LR: likelihood ratio; MoM: multiple of the
median.
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18.3–31.7 pg/ml), median levels of PlGF in ﬁrst trimester
were signiﬁcantly lower for women subsequently diag-
nosed with pregnancy hypertension (median PlGF 21.3,
IQR: 16.9–28.0 pg/ml; P < 0.001). Compared with unaf-
fected pregnancies, women with pregnancy hypertension
and pre-eclampsia had a tendency to have lower sFlt-1 lev-
els, but differences were not signiﬁcant (Table 1).
Fig. 1 presents the distribution of log sﬂt-1 (MoM) and
log PlGF (MoM) for women with and women without preg-
nancy hypertension and pre-eclampsia. There was no dif-
ference in the distribution of log PlGF and log sFlt-1comparing women with and without pregnancy
hypertension and pre-eclampsia. Table 2 presents the pre-
dictive accuracy results for pregnancy hypertension and
pre-eclampsia for all women. The area under the curve
(AUC) for univariate models evaluating individual bio-
markers was no different to chance, but for all three bio-
markers combined, AUC was 0.55 (P = 0.005). Parity and
previous diagnosed hypertension had better predictive
accuracy than serum biomarkers (AUC = 0.64, P < 0.001)
and predictive accuracy for all maternal and clinical infor-
mation was fair (AUC = 0.70, P < 0.001 for pregnancy
hypertension and AUC = 0.74, P < 0.001 for pre-eclampsia).
Table 3
Accuracy of models using serum biomarker levels and maternal and clinical information in early pregnancy to predict pregnancy hypertension based on a 5%
false positive rate in nulliparous women.









Pregnancy hypertension (n = 118)
PlGF MoM 0.57 (0.51, 0.63) 0.02 6.0 (2.4, 11.9) 11.5 (4.4, 22.2) 90.3 (88.5, 92.0) 1.20
sFlt-1 MoM 0.52 (0.46, 0.57) 0.5 5.3 (2.0, 11.2) 10.2 (3.8, 20.8) 90.5 (88.6, 92.1) 1.07
PAPP-A MoM 0.54 (0.49, 0.60) 0.11 6.8 (3.0, 12.9) 12.1 (5.4, 22.5) 90.3 (88.4, 92.0) 1.26
Serum Biomarkers only 0.57 (0.52, 0.63) 0.01 4.4 (1.5, 10.0) 8.5 (2.8, 18.7) 90.4 (88.5, 92.0) 0.87
Maternal weight 0.61 (0.55, 0.67) 0.0001 19.5 (12.8, 27.8) 29.9 (20.0, 41.4) 91.6 (89.8, 93.1) 3.92
All maternal and clinical
information onlya
0.68 (0.63, 0.74) <0.0001 25.6 (18.0, 34.5) 36.1 (25.9, 47.4) 92.1 (90.3, 93.6) 5.16
Combined – biomarkers + maternal
and clinical information
0.70 (0.65, 0.75) <0.0001 26.8 (18.9, 36.0) 36.1 (25.9, 47.4) 92.4 (90.7, 93.9) 5.31
Pre-eclampsia (n = 44)
PlGF MoM 0.49 (0.39, 0.59) 0.9 9.1 (2.5, 21.7) 6.5 (1.8, 15.7) 96.5 (95.2, 97.5) 1.81
sFlt-1 MoM 0.58 (0.49, 0.66) 0.07 9.1 (2.5, 21.7) 6.6 (1.8, 15.9) 96.4 (95.2, 97.4) 1.82
PAPP-A MoM 0.54 (0.45, 0.63) 0.3 11.4 (3.8, 24.6) 7.6 (2.5, 16.8) 96.6 (95.3, 97.5) 2.15
Serum Biomarkers only 0.58 (0.49, 0.67) 0.07 11.4 (3.8, 24.6) 8.1 (2.7, 17.8) 96.5 (95.3, 97.5) 2.26
Maternal weight 0.63 (0.55, 0.71) 0.002 18.2 (8.2, 32.7) 12.1 (5.4, 22.5) 96.8 (95.6, 97.8) 3.63
All maternal and clinical
information onlya
0.71 (0.64, 0.78) <0.0001 20.5 (9.8, 35.3) 13.6 (6.4, 24.3) 96.9 (95.7, 97.8) 4.09
Combined – biomarkers + maternal
and clinical information
0.74 (0.66, 0.81) <0.0001 25.0 (13.2, 40.3) 16.4 (8.5, 27.5) 97.0 (95.8, 97.9) 4.99
a Including: maternal weight, smoking during pregnancy, parity, previously diagnosed hypertension, previously diagnosed diabetes, high blood pressure
recorded during pregnancy and country of birth; PPV: positive likelihood ratio; NPV: negative predictive value; LR: likelihood ratio; MoM: multiple of the
median.
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improve the ability of the models to predict pregnancy
hypertension or pre-eclampsia (X2 = 2.70, P = 0.10 for GH;
and X2 = 1.24, P = 0.27 for pre-eclampsia).
Table 3 presents the predictive accuracy results for
pregnancy hypertension and pre-eclampsia for nulliparous
women only. The AUC results for individual biomarkers
were similar compared to those for all women. Maternal
weight had better predictive accuracy than serum bio-
markers (AUC = 0.61, P < 0.001) and predictive accuracy
of all maternal and clinical information was similar to all
women (Table 3). Including serum biomarkers with mater-
nal risk factors did not improve the ability of the models to
predict pregnancy hypertension or pre-eclampsia
(X2 = 3.00, P = 0.08 for pregnancy hypertension; and
X2 = 0.97, P = 0.32 for pre-eclampsia) (Table 3). In analyses
for all and for nulliparous women, the positive likelihood
ratio results for maternal and clinical risk factors were
superior, ranging between 4.09 and 5.25 (Tables 2 and 3).Discussion
This is one of the largest studies to investigate the accu-
racy of sFlt-1 and PlGF in early pregnancy in predicting
pregnancy hypertension and pre-eclampsia. It also pro-
vides an important comparison of the utility of serum bio-
markers with maternal and clinical risk factors. Although
sFlt-1 and PlGF levels were generally lower among women
subsequently diagnosed with pregnancy hypertension and
pre-eclampsia, our results indicate that the predictive
accuracies of ﬁrst trimester serum concentrations of sFlt-
1 and PlGF were insufﬁcient in predicting these outcomes.Clinical and maternal risk factors had fair predictive
accuracy and outperformed a combination of these ﬁrst tri-
mester serum biomarkers. Adding serum sFlt-1, PlGF and
PAPP-A levels to risk factors did not improve the accuracy
of models in predicting pregnancy hypertension and pre-
eclampsia, even when limiting the analysis to nulliparous
women.
Consistent with most previous studies we found little or
no difference in sFlt-1 or PlGF levels in ﬁrst trimester
between women with and without subsequent pre-
eclampsia [3,17–22]; and poor accuracy in predicting any
pre-eclampsia or pre-eclampsia >34 weeks [23–25]. This
includes a large population-based prospective cohort study
of 7,519 women, highlighting little association and no
potential predictive ability between sFlt-1 or PlGF and
pre-eclampsia [3]. In contrast, three studies reported a po-
tential utility of sFlt-1 or PlGF levels in ﬁrst trimester for
predicting any pre-eclampsia or pre-eclampsia <34 weeks
(based on a 10% ﬁxed false positive rate, sensitivity ranging
between 0.33 and 0.58 and AUC between 0.65 and 0.83,
respectively) [26–28]. Promising results have been also re-
ported for PlGF in predicting early (<34 weeks) or severe
pre-eclampsia (based on a 5% ﬁxed false positive rate, sen-
sitivity: 0.28–0.30; AUC: 0.75–0.80, respectively)
[26,29,30], however, we could not assess the accuracy for
this outcome due to the low number of cases in our cohort.
The accuracy of sFlt-1 and PlGF alone in predicting pre-
eclampsia in nulliparous women has been investigated
by three other studies [30–32], in addition to ours. In all
studies, results for sFlt-1 were comparable with ours, but
in other studies PlGF performed better in predicting pre-
eclampsia in this sub-group of women. The studies re-
ported an AUC for PlGF in predicting any pre-eclampsia
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for pre-eclampsia <37 weeks [32]. Factors that may inﬂu-
ence variation in predictive accuracy results and biomarker
concentrations include the timing of the sampling, timing
of the onset of disease and whether levels were standard-
ized or not to MoM values.
The main issue attributed to the lack of predictive abil-
ity of sFlt-1 and PlGF in early pregnancy is that imbalances
between pro and anti angiogenic factors involved in the
pathogenesis of pre-eclampsia, may not be expressed until
later in pregnancy. Longitudinal studies of serum sFlt-1
and PlGF [3,20,22,24] have demonstrated that the associa-
tion of levels with pre-eclampsia strengthens with the
course of pregnancy, but that these would not be clinically
useful in predicting pre-eclampsia until third trimester
[24]. Furthermore, better predictive accuracy has been re-
ported with testing in second trimester [33], but screening
at 2nd or 3rd trimester may be too late for preventive
interventions to be effective. The potential advantages of
ﬁrst trimester screening include the opportunity to incor-
porate an additional test into existing, routine antenatal
testing for identiﬁcation of at-risk pregnancies for closer
surveillance. In addition, early implementation of dietary
and lifestyle interventions [34] or low-dose aspirin [35]
in these pregnancies, may reduce the risk of pre-eclampsia.
Compared with serum biomarker information alone, we
found maternal and clinical risk factors, speciﬁcally parity,
previously diagnosed hypertension and maternal weight
provide greater predictive value. And, when sFlt-1 or PlGF
information is added to these combined, neither biomarker
provided any additional predictive information. In other
studies, the addition of PlGF to maternal risk factors im-
proves the predictive accuracy, but the signiﬁcance of this
was not reported (relative increase in AUC ranging be-
tween 5% and 16%) [26,30–32]. Although, our LR results
for clinical risk factors revealed these would be three to
ﬁve times more likely to be present in women with, as op-
posed to women without, pregnancy hypertension or pre-
eclampsia, these LR values are still only considered to be
indicative of a relatively small likelihood of disease [36].
A systematic review of risk factors for pre-eclampsia re-
vealed that there are a broad range of other important risk
factors that are also important to be taken into account,
but we did not have information on, such as the presence
of antiphospholipid antibodies or family history of hyper-
tension [5]. Overall, our results highlight that complete
maternal risk factor information compared with any serum
biomarker tested in early pregnancy would potentially
provide much better information in predicting hyperten-
sive disorders in pregnancy.
Some of the potential limitations of the study include
the lower prevalence of pre-eclampsia (2.5%) compared
with the maternity population in NSW (3.1%) [37] which
may be due to a healthier and more afﬂuent cohort. Mater-
nal weight was missing in 21% of the women, although this
was addressed by applying multiple imputations, which
has shown to be a robust and valid technique for dealing
with missing data [14]. Despite these, strengths of this
study were the assessment of an unselected consecutive
cohort of women attending ﬁrst trimester screening. Re-
cord linkage of laboratory to birth and hospital data alsoensured follow up and ascertainment of pregnancy out-
comes with only minimal missing information. Missing
health and pregnancy information was mostly attributable
to women giving birth in hospitals out of state, although,
these women had similar characteristics compared with
those included in the study.
In conclusion, our ﬁndings suggest that maternal ﬁrst
trimester serum concentrations of sFlt-1 and PlGF do not
predict pregnancy hypertension and pre-eclampsia any
better than routinely assessed clinical and maternal risk
factor information. Screening for sFlt-1 and PlGF levels in
early pregnancy would not predict those pregnancies at-
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